Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with...
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company,...
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding...
DENVER, Jan. 21, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in...
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE)...
The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the...
Event Sponsored by LIXTE Biotechnology Holdings,Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by...
California joins 23 other states eligible to receive free neffy® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026...
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission...
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage...
MINNEAPOLIS, MN, Jan. 21, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., in cooperation with its parent PetVivo Holdings, Inc....
Multi-year Sponsorship Expands Across Texas and California with Educational Resources, Community Leadership and Patient SupportBAKERSFIELD, Calif. and AUSTIN, Texas, Jan....
Dallas-based Restore Brain expands in Missouri, celebrating one year of advanced psychiatric care with innovative TMS and SPRAVATO® treatments Restore...
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patientsBURLINGTON, Mass. and JERUSALEM,...
TORONTO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) announced today its voluntarily decision...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for...
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on...
Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while...
Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the...